Eli Lilly targets alleged black market sales of its experimental GLP-1 drug
Summary
Eli Lilly is suing six U.S. groups that it says are illegally selling its experimental weight loss drug, retatrutide, on the black market. The company says these sellers include pharmacies, medical spas, and online stores that claim the drug is only for research, but actually sell it for weight loss.Key Facts
- Eli Lilly is taking legal action against six U.S. entities.
- These entities include compounding pharmacies, medical spas, and online sellers.
- The lawsuit claims these groups sell illegal versions of retatrutide.
- Retatrutide is an experimental drug designed for weight loss.
- Sellers falsely state their products are meant only for research purposes.
- The company aims to stop unauthorized black market sales of its drug.
- Retatrutide is not yet fully approved for general consumer use.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.
